Lubner David Charles
SEC Form 4 insider trading activity
Lubner David Charles has filed 3 SEC Form 4 filings (4 transaction rows) across 3 companies, including BRVE, DYN, ACLX, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Aug 7, 2026.
On the most recent filing, Lubner David Charles is listed as Director at Braveheart Bio, Inc. Inside the rolling window, Lubner David Charles reported 1 open-market purchase totaling $1000K in BRVE and 1 open-market sale totaling $450K in ACLX. The largest disclosed transaction in the window is a purchase of 55,555 BRVE shares on Aug 7, 2026, worth $1000K.
Companies traded
Other insiders at BRVE
Insider Buying
$1000K
reported purchases (SEC code P)
Insider Selling
$450K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lubner David Charles made?
Lubner David Charles has filed 3 SEC Form 4 filings (4 transaction rows) across 3 companies, including BRVE, DYN, ACLX since 2026.
Which companies does Lubner David Charles trade?
Lubner David Charles has filed SEC Form 4 disclosures for 3 companies, including BRVE, DYN, ACLX.
When was Lubner David Charles's most recent SEC Form 4 filing?
Lubner David Charles's most recent SEC Form 4 filing on Tracefour is dated Aug 7, 2026.
What is Lubner David Charles's total buy and sell value in the current window?
Inside the rolling retention window, Lubner David Charles bought $1000K and sold $450K based on SEC Form 4 filings.
What was Lubner David Charles's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 55,555 BRVE shares on 2026-08-07, worth $1000K, per SEC Form 4 filings.